Current Assets
Cash & Equivalents
Royalty Pharma Cash & Equivalents decreased by 5.2% to $586.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 46.1%, from $1.09B to $586.40M. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -9.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ4 2013
Last reportedQ1 2026
How to read this metric
Higher levels indicate strong liquidity and financial flexibility; lower levels may signal potential cash flow issues.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and short-term inve...
Peer comparison
A universal metric for assessing a company's immediate financial health.
Metric ID:
cash_and_equivalentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.14B | $1.80B | $1.54B | $1.79B | $2.11B | $991.63M | $1.71B | $1.98B | $2.17B | $936.45M | $477.01M | $843.00M | $1.76B | $950.05M | $929.03M | $1.09B | $631.91M | $938.94M | $618.70M | $586.40M |
| QoQ Change | — | +57.7% | -14.4% | +16.3% | +17.7% | -53.0% | +72.5% | +15.5% | +10.0% | -56.9% | -49.1% | +76.7% | +109.3% | -46.2% | -2.2% | +17.1% | -41.9% | +48.6% | -34.1% | -5.2% |
| YoY Change | — | — | — | — | +84.5% | -44.9% | +11.0% | +10.3% | +3.1% | -5.6% | -72.1% | -57.3% | -18.8% | +1.5% | +94.8% | +29.0% | -64.2% | -1.2% | -33.4% | -46.1% |
Range$477.01M – $2.17B
CAGR-13.1%
Avg YoY Growth-6.8%
Median YoY Growth-3.4%
Current Streak2 quarters decline
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's cash & equivalents?
- Royalty Pharma (RPRX) reported cash & equivalents of $586.40M in Q1 2026.
- How has Royalty Pharma's cash & equivalents changed year-over-year?
- Royalty Pharma's cash & equivalents decreased by 46.1% year-over-year, from $1.09B to $586.40M.
- What is the long-term trend for Royalty Pharma's cash & equivalents?
- Over 5 years (2020 to 2025), Royalty Pharma's cash & equivalents has grown at a -9.3% compound annual growth rate (CAGR), from $1.01B to $618.70M.
- What does cash & equivalents mean?
- Cash and highly liquid assets that can be converted to cash within 90 days.